{3-[(4-aminomethyl-benzyl)tert-butoxycarbonyl-amino]-propyl}-cyclohexyl-carbamic acid tert-butyl ester | 917021-06-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {3-[(4-aminomethyl-benzyl)tert-butoxycarbonyl-amino]-propyl}-cyclohexyl-carbamic acid tert-butyl ester
• 英文别名: Tert-butyl (4-(aminomethyl)benzyl)(3-((tert-butoxycarbonyl)(cyclohexyl)amino)propyl)carbamate；tert-butyl N-[[4-(aminomethyl)phenyl]methyl]-N-[3-[cyclohexyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propyl]carbamate
• CAS: 917021-06-8
• 化学式: C₂₇H₄₅N₃O₄
• 分子量: 475.672
• InChiKey: FFWMVIQHAQPNJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  34
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  85.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  {3-[(4-aminomethyl-benzyl)tert-butoxycarbonyl-amino]-propyl}-cyclohexyl-carbamic acid tert-butyl ester 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 18.0h， 生成 tert-butyl N-[[4-(aminomethyl)cyclohexyl]methyl]-N-[3-[cyclohexyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propyl]carbamate
  参考文献：
  名称：

  Pyrimidine compounds

  摘要：

  这项发明涉及一种治疗炎症性疾病或免疫性疾病、发育性或退行性疾病或组织损伤的方法。该方法包括向需要的受试者施用一种或多种式(I)化合物的有效量。该式中的每个变量在说明书中有定义。

  公开号：

  US20060281712A1
• 作为产物：
  描述：

  N-(3-氨丙基)环己胺 在 ammonium hydroxide 、 氢气 、 sodium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 叔丁醇 为溶剂， 反应 6.0h， 生成 {3-[(4-aminomethyl-benzyl)tert-butoxycarbonyl-amino]-propyl}-cyclohexyl-carbamic acid tert-butyl ester
  参考文献：
  名称：

  NOVEL CXCR4 ANTAGONISTS WITH AMINO ACID SKELETON, PREPARATION THEREFOR AND BIOMEDICAL USE THEREOF

  摘要：

  本发明提供一种由式(I)表示的化合物，或其药用可接受的盐或前药。

  公开号：

  US20200268729A1

文献信息

• Heterocyclic Compounds
  申请人：Yen Chi-Feng

  公开号：US20090264339A1

  公开（公告）日：2009-10-22

  This invention relates to heterocyclic compounds of the formulas shown in the specification. It also relates to methods for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, and tissue injuries with one of the heterocyclic compounds.

  这项发明涉及规范中所示的异环化合物。它还涉及使用其中一种异环化合物治疗炎症性疾病或免疫性疾病、发育性或退行性疾病以及组织损伤的方法。
• Stem Cell Mobilizers Targeting Chemokine Receptor CXCR4: Renoprotective Application in Acute Kidney Injury
  作者：Chien-Huang Wu、Jen-Shin Song、Kuei-Hua Chang、Jiing-Jyh Jan、Chiung-Tong Chen、Ming-Chen Chou、Kai-Chia Yeh、Ying-Chieh Wong、Chen-Tso Tseng、Szu-Huei Wu、Ching-Fang Yeh、Chung-Yu Huang、Min-Hsien Wang、Amit A. Sadani、Chun-Ping Chang、Chia-Yi Cheng、Lun K. Tsou、Kak-Shan Shia

  DOI：10.1021/jm501769r

  日期：2015.3.12

  We have discovered a novel series of quinazoline-based CXCR4 antagonists. Of these, compound 19 mobilized CXCR4(+) cell types, including hematopoietic stem cells and endothelial progenitor cells, more efficiently than the marketed 1 (AMD3100) with subcutaneous administration at the same dose (6 mg/kg) in mice. This series of compounds thus provides a set of valuable tools to study diseases mediated by the CXCR4/SDF-1 axis, including myocardial infarction, ischemic stroke, and cancer metastasis. More importantly, treatment with compound 19 significantly lowered levels of blood urea nitrogen and serum creatinine in rats with renal ischemia-reperfusion injury, providing evidence for its therapeutic potential in preventing ischemic acute kidney injury. CXCR4 antagonists such as 19 might also be useful to increase circulating levels of adult stem cells, thereby exerting beneficial effects on damaged and/or inflamed tissues in diseases that currently are not treated by standard approaches.
• Function-Oriented Development of CXCR4 Antagonists as Selective Human Immunodeficiency Virus (HIV)-1 Entry Inhibitors
  作者：Chien-Huang Wu、Chuan-Jen Wang、Chun-Ping Chang、Yung-Chi Cheng、Jen-Shin Song、Jiing-Jyh Jan、Ming-Chen Chou、Yi-Yu Ke、Jing Ma、Ying-Chieh Wong、Tsung-Chih Hsieh、Yun-Chen Tien、Elizabeth A. Gullen、Chen-Fu Lo、Chia-Yi Cheng、Yu-Wei Liu、Amit A. Sadani、Chia-Hua Tsai、Hsin-Pang Hsieh、Lun K. Tsou、Kak-Shan Shia

  DOI：10.1021/jm501772w

  日期：2015.2.12

  Motivated by the pivotal role of CXCR4 as an HIV entry co-receptor, we herein report a de novo hit-to-lead effort on the identification of subnanomolar purine-based CXCR4 antagonists against HIV-1 infection. Compound 24, with an EC50 of 0.5 nM against HIV-1 entry into host cells and an IC50 of 16.4 nM for inhibition of radioligand stromal-derived factor-1a (SDF-1a) binding to CXCR4, was also found to be highly selective against closely related chemokine receptors. We rationalized that compound 24 complementarily interacted with the critical CXCR4 residues that are essential for binding to HIV-1 gp120 V3 loop and subsequent viral entry. Compound 24 showed a 130-fold increase in anti-HIV activity compared to that of the marketed CXCR4 antagonist, AMD3100 (Plerixafor), whereas both compounds exhibited similar potency in mobilization of CXCR4(+)/CD34(+) stem cells at a high dose. Our study offers insight into the design of anti-HIV therapeutics devoid of major interference with SDF-1 alpha function.
• PYRIMIDINE COMPOUNDS
  申请人：Yen Chi-Feng

  公开号：US20090143302A1

  公开（公告）日：2009-06-04

  This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of one or more compounds of formula (I). Each variable in this formula is defined in the specification.
• US7589197B2
  申请人：——

  公开号：US7589197B2

  公开（公告）日：2009-09-15